Skip to search formSkip to main contentSkip to account menu

aviscumine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 1861: Aviscumine (ME-503) suppresses the growth of melanoma by potentially targeting c-Myc pathway
Aviscumine, a recombinant mistletoe lectin I, is produced in E. coli and has been evaluated for its antitumor activities in… 
2016
2016
Abstract CT123: Aviscumine (ME-503), a plant protein with a novel mode of action, shows clinical activity in unresectable stage IV metastatic melanoma: data from a phase II trial
Background: Aviscumine, a recombinant protein, inactivates the 28S rRNA (“ribotoxic stress”) after endocytosis and enhances… 
2014
2014
P24. Aviscumine enhances NK- cytotoxicity against tumor cells
Meeting abstracts The mistletoe lectin I belongs to a new class of anticancer drugs with type II ribosomal inhibitor activity… 
2009
2009
Binding of Recombinant Mistletoe Lectin (Aviscumine)
Background: Lectins, carbohydrate proteins, bind to glycoconjugates of all mammalian cells, including cancer cells. Aberrant… 
2008
2008
Gateways to clinical trials. December 2008.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2004
2004
Phase I evaluation of the weekly 24 hour intravenous administration of aviscumine, a recombinant ribosome-inactivating protein, in patients with refractory solid tumors
3106 Background Aviscumine is a recombinant E.coli-derived type II ribosome-inactivating protein with potent antitumor activity… 
2004
2004
Phase I evaluation of the weekly 24 hour intravenous administration of aviscumine, a recombinant ribosome-inactivating protein, in patients with refractory solid tumors.
3106 Background Aviscumine is a recombinant E.coli-derived type II ribosome-inactivating protein with potent antitumor activity… 
2003
2003
Effect of excipients on the stability and aerosol performance of nebulized aviscumine.
Pulmonary delivery is an attractive alternative route to deliver protein drugs that are currently delivered by injection… 
2003
2003
Lyoprotection of aviscumine with low molecular weight dextrans.
2003
2003
Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)